Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
third rock ventures
6
×
clinical trials
boston
cancer
ipo
new york blog main
san francisco
san francisco blog main
san francisco top stories
startups
warp drive bio
cancer drugs
deals
gene therapy
investing
new york top stories
revolution medicines
sanofi
the column group
venture capital
acetylon pharmaceuticals
adeno-associated virus
ally bridge group
ambys medicines
amgen
antisense oligonucleotide
benzodiazepines
big data analytics
biogen
blackrock
blackstone group
blackstone life sciences
casdin capital
cell therapy
What
medicines
6
×
ipo
new
research
aiming
biotech
cancer
diseases
drug
drugs
genetic
proteins
revolution
adding
ago
aims
ambys
analysis
backed
balance
big
bio
bring
build
cancer’s
cause
ceo
company
control
deadly
deal
debuted
decibel
despite
develop
disease
emerged
employing
epilepsy
family
Language
unset
Current search:
medicines
×
" third rock ventures "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?